Use of antiepileptic drugs and lipid-lowering agents in the United States

[1]  M. Brodie,et al.  Enzyme induction with antiepileptic drugs: Cause for concern? , 2013, Epilepsia.

[2]  Cheng-Hsien Lu,et al.  Effects of long‐term antiepileptic drug monotherapy on vascular risk factors and atherosclerosis , 2012, Epilepsia.

[3]  S. Candrilli,et al.  The association between antiepileptic drug and HMG-CoA reductase inhibitor co-medication and cholesterol management in patients with epilepsy , 2010, Epilepsy Research.

[4]  S. Mintzer,et al.  Antiepileptic Drugs and Markers of Vascular Risk , 2010, Current treatment options in neurology.

[5]  S. Mintzer.  Metabolic consequences of antiepileptic drugs , 2010, Current opinion in neurology.

[6]  M. Sperling,et al.  Effects of antiepileptic drugs on lipids, homocysteine, and C‐reactive protein , 2009, Annals of neurology.

[7]  G. Le Teuff,et al.  Assessment of potential drug interactions in patients with epilepsy , 2009, Neurology.

[8]  C. Harden,et al.  Optimizing therapy of seizures in women who use oral contraceptives , 2006, Neurology.

[9]  M. Morrell,et al.  Treatment of epilepsy in adults: expert opinion, 2005 , 2005, Epilepsy & Behavior.

[10]  T. Nabeshima,et al.  The high atherosclerotic risk among epileptics: the atheroprotective role of multivitamins. , 2005, Journal of pharmacological sciences.

[11]  M. Brodie,et al.  Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy , 1999, Epilepsy Research.

[12]  H. Hunter.  The treatment of epilepsy. , 1948 .

[13]  F. Talbot.  Treatment of Epilepsy , 1931 .